Longeveron Inc. (LGVN) SEC Filings & Earnings Calls

Loss of CMO could delay clinical programs or regulatory interactions; no successor or transition plan disclosed.

“CMO departure effective immediately; no advisory role or transition details.”

Trial failure may jeopardize laromestrocel program and company viability.

“The ELPIS II trial did not meet the primary efficacy endpoint” · word for word

Delisting risk resolved; no further compliance issues noted.

“Regained compliance with Nasdaq minimum bid price requirement.”

Nasdaq delisting risk mitigated by reverse split, but share price still low; potential for further dilution if price falls again.

“reverse stock split... to enable the Company to regain compliance with the $1.00 per share minimum bid price requirement”

CFO transition risk; new CFO may need time to acclimate, but prior CFO remains in controller role providing continuity.

“Marie Washburn... will remain with the Company in her prior role of Vice President and Corporate Controller”

Clinical trial failure risk for ELPIS II; no revenue yet; cash burn.

“Clinical stage biotech with no approved products; upcoming data readout carries binary risk.”

Going concern risk

“We do not have sufficient cash to meet our minimum expenditure commitments for one year from the date these unaudited condensed financial statements are available to be issued, and therefore we need to raise additional funds to continue as a going concern.” · word for word

FDA regulatory setback for HLHS

“the FDA indicated that given the interim analysis mandated and conducted by the National Institute of Health (NIH) during the trial (to which the Company was and remains blinded), a new primary endpoint could not be agreed to while the trial is still ongoing.” · word for word

Dilution risk from equity financing

“warrants exercisable for an aggregate of up to 21,238,731 shares of our Class A common stock remain outstanding at exercise prices ranging from $0.65 per share to $175.00 per share.” · word for word

ATM facility restrictions

“the ATM facility was under a standstill restriction until June 9, 2026, and thereafter we have restrictions in place regarding our ability to use the ATM facility unless our Class A common stock is trading above $0.80 per share until September 7, 2026.” · word for word

Temporary non-compliance with Nasdaq listing rule resolved; low residual risk.

“temporarily failed to be in compliance with Nasdaq Listing Rule 5605(c)(2)(A)” · word for word

Potential dilution from equity awards; 1 million shares total, but vesting over 3 years limits near-term impact.

“500,000 restricted stock units... 100,000 RSUs and 400,000 non-qualified stock options”

Authorized share increase enables future dilution; no immediate issuance but signals potential equity financing.

“increase the number of authorized shares of Class A common stock to 175,000,000 shares” · word for word

Nasdaq Delisting Risk

“On the Record Date, the last reported sale price of our Class A Common Stock on Nasdaq was $0.8379 per share.” · word for word

Going Concern Risk

“The Company implemented a temporary 50% reduction in the compensation of the Company’s CEO and its Executive Chairman/CSO. A temporary 25% reduction in the compensation of the Company’s C-suite officers was also implemented.” · word for word

Dilution Risk

“The Share Increase Amendment would increase the number of authorized shares of Class A Common Stock from 84,295,000 to 175,000,000 shares.” · word for word

Clinical trial risk; Phase 2b results pending.

“Topline results from Phase 2b anticipated in August 2026.”

Going Concern Uncertainty

“We do not have sufficient cash to meet our minimum expenditure commitments for one year from the date these unaudited condensed financial statements are available to be issued, and therefore we need to raise additional funds to continue as a going concern.” · word for word

FDA Regulatory Setback for HLHS Program

“The FDA no longer refers to the ELPIS II trial as pivotal, as had been specifically discussed in the Company’s Type C meeting in 2024.” · word for word

Dilution Risk from Financing

“Warrants exercisable for an aggregate of up to 22,434,760 shares of our Class A common stock remain outstanding at exercise prices ranging from $0.65 per share to $175.00 per share.” · word for word

Going concern risk

“Our recurring losses from operations and negative cash flow raise substantial doubt about our ability to continue as a going concern without sufficient capital resources and we have included an explanatory paragraph in the notes to our financial statements for the year ended December 31, 2025, with respect to this uncertainty.” · word for word

No approved products

“We have no products approved for commercial sale and have not generated any material revenue from product sales.” · word for word

Regulatory uncertainty for Frailty indication

“According to the FDA, 'Aging-related Frailty' does not have a definition that is acceptable for characterizing the conditions for regulatory purposes, and there are no precedents for regulatory approvals of this indication.” · word for word

Going concern uncertainty

“The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern.” · word for word

Dependence on future financing

“We intend to seek additional financing opportunities, capital raises, as well as non-dilutive funding options to support our operating plans. There can be no assurance we will be able to attain future financing at terms favorable to us or at all.” · word for word

Clinical trial risk

“We do not yet have a product that has been approved by the FDA, and have only generated revenues from grants, the Bahamas Registry Trials and contract manufacturing.” · word for word

Regulatory delay risk from government shutdown

“A further prolonged federal government shutdown could delay regulatory feedback, clinical-site activation, or data-submission schedules; postpone the review or award of grant funding; and affect the timing or completion of public or private financing transactions” · word for word

Dilution risk from equity offerings

“To the extent that we raise additional capital through the sale of convertible debt or equity securities, current stockholder ownership interest will be diluted” · word for word

Clinical trial risk: ELPIS II results not expected until Q3 2026; BLA submission delayed to 2027.

“Top-line trial results anticipated Q3 2026; BLA submission now anticipated in 2027.”

Financing risk: DCM trial initiation subject to obtaining necessary financing.

“Company currently anticipates initiation of pivotal Phase 2 clinical trial in 2026, subject to obtaining necessary financing.”

Cash runway management: extension of timeline for BLA submission to preserve cash.

“BLA submission delayed based on operational decisions to extend the cash runway.”